Repros Therapeutics Inc.' Proellex®-V Topline Analysis Suggests 12 Mg Dose Effective and Well Tolerated in Phase 2 for Uterine Fibroids

Published: Jan 03, 2013

THE WOODLANDS, Texas, Jan. 3, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported top line results from its Phase 2 study of vaginally administered Proellex in the treatment of symptomatic fibroids. The results from the study suggest the 12 mg dose may provide clinical benefit to women suffering from symptomatic uterine fibroids. The Company plans to request an end of Phase 2 meeting with the FDA as soon as practicable.

Back to news